Vensica closes $19 million investment round

Vensica Therapeutics, a clinical stage biopharmaceutical company, has closed a $19 million investment round. Vensica executed a strategic collaboration agreement with Merz Therapeutics in 2021 and the Merz Group is participating in Vensica’s financing with up to $3 million, bringing the total round to up to $19 million. The round was led by Israel Biotech Fund (IBF) with the participation of Laborie, Lew Pell, Agriline, and The Trendlines Group.

Merz Therapeutics, a business of the Merz Group, is a leader in the field of neurotoxins. Vensica has exclusively licensed Merz’s botulinum neurotoxin A (Xeomin®) for needle-free use in urological procedures.

Vensica is unlocking the potential of neurotoxins in urology by developing minimally invasive solutions using the unique properties of therapeutic ultrasound to deliver botulinum toxin A to the bladder. Vensica’s needle-free drug delivery platform is intended for the treatment of urological indications, including overactive bladder, neurogenic bladder, and interstitial cystitis. Today’s gold standard treatment requires needle injections of the neurotoxin into the bladder wall. Vensica’s needle-free platform is expected to enable a far superior patient experience resolving needle-associated issues including pain, and urinary retention, making a generally more complicated procedure easier. Vensica’s platform is anticipated to facilitate more efficacious treatment through more uniform delivery of the neurotoxin to the bladder wall.

The funds raised will support the company’s phase II multicenter clinical trials in Europe and the USA. Vensica is expanding its workforce in Israel for next-stage clinical and regulatory development of its device, together with Merz Therapeutics’ XEOMIN®, focusing on overactive bladder treatment.

News of this investment appeared in Geektime, PR Newswire and Yahoo Finance and Merz Therapeutics.